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v Ovarian stimulation prior in-vitro fertilization (IVF) causes a significant increase in serum 
estradiol levels which may influence hemostasis. 
v Activated protein C (APC) resistance is a sensitive coagulation biomarker to the use of 
hormonal therapies (e.g., combined oral contraceptives (COC))
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AIM
To assess the resistance towards the
APC in women undergoing ovarian
stimulation for IVF, using the
endogenous thrombin potential
(ETP)-based APC resistance assay .
METHOD
v Resistance to APC was assessed on the Calibrated Automated Thrombogram (CAT) with Thrombinoscope software (version 5.0),
using commercially available CE-marked thrombin generation dedicated kit reagents from Diagnostica Stago.
v Ten women undergoing ovarian stimulation for IVF were enrolled and displayed the following characteristics (Table 1):
Patient Age BMI Genetic mutation ? Hormonal treatment Composition 
Treatment 
duration
01 33 24,7 n/d Menopur 150 Menotropin (HMG) 12 days
02 38 16,1 NO Meriofert 150 Menotropin (HMG) + hCG 20 days
03 29 15 FVL hetero Puregon 100 Follitropin beta (recombinant FSH) 10 days
04 34 16,9 NO Menopur 150 Menotropin (HMG) 12 days
05 31 20,5 NO Gonal F 300 Progynova 
Follitropin alpha (recombinant FSH) 
Estradiol valerate 2 mg 10 days
06 38 20 NO Progeffik 100Prontogest 100
Progesterone
Progesterone 10 days
07 36 16,3 G20210A hetero
Gonal F 300
Ovitrelle 
Follitropin alpha (recombinant FSH) 
Choriogonadotropine alfa (hCG) 12 days
08 31 17,1 NO Progeffik Progesterone 10 days
09 36 19,4 G20210A hetero
Gonal F 300
Menopur 75
Follitropin alpha (recombinant FSH) 
Menotropin (HMG) 15 days
10 37 16,3 NO Progeffik 200 Progesterone 10 days
v The investigated thrombin generation parameter was
the endogenous thrombin potential (ETP),
corresponding to the area under the thrombin
generation curve.
v Resistance to APC was expressed in normalized APC 
sensitivity ratio (nAPCsr) computed as following:
!𝑆𝑎𝑚𝑝𝑙𝑒 𝐸𝑇𝑃 (+𝐴𝑃𝐶) 𝑆𝑎𝑚𝑝𝑙𝑒 𝐸𝑇𝑃 (−𝐴𝑃𝐶)
!𝑅𝑒𝑓𝑒𝑟𝑒𝑛𝑐𝑒 𝑝𝑙𝑎𝑠𝑚𝑎 𝐸𝑇𝑃 (+𝐴𝑃𝐶) 𝑅𝑒𝑓𝑒𝑟𝑒𝑛𝑐𝑒 𝑝𝑙𝑎𝑠𝑚𝑎 𝐸𝑇𝑃 (−𝐴𝑃𝐶)
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CONCLUSION
This pilot study showed that ovarian stimulation with FSH agonist (HMG or follitropin) had 
little impact on APC resistance. On the the other hand, estradiol seemed to induce a slight 
APC resistance, which has already been observed in women using estradiol-containing COC. 
However, further investigations are needed to confirm these results. 
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v Ovarian stimulation appeared to have little impact on APC resistance. The majority of 
results were within the normal ranges of 0 to 2.08 (Figure 1A and Table 2)
v A resistance to APC was expected for patient 03 as she is carrier of a heterozygous factor 
V Leiden mutation (Figure 1C). 
v The slight resistance to APC observed for patient 05 could be related to the use of 
estradiol (Progynova)(Figure 1B)
v The patient 08 had an abnormally low thrombin generation curve without APC. This 
could be explained by the use of an anticoagulant drug (Figure 1D)
PERSPECTIVES
v An anti-Xa activity test will be 
performed for patient 08. 
v Dosage of FII, FVIII, protein S and 
protein C will be performed for all 
samples
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Figure 1 : Thrombin generation in absence of APC (blue curve) and in presence of APC (red curve) for patients 01, 05, 03 and 08. 
Table 1: Characteristics (age, BMI, genetic mutation, hormonal treatment, its composition and duration of treatment) of 
patients included. 
Table 2: nAPCsr values of patient 
samples. Normal ranges stand between [0-2.08] 
